Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy

Table 5 Multivariate analysis of factors affecting the disease-free survival

Characteristic	Multivariate analysis
	Model 1		Model 2
	HR (95%CI)	P value	HR (95%CI)	P value
Pre-NCRT CEA (< 3.55/> 3.55)	0.512 (0.226-1.162)	0.109
Pre-NCRT CA19-9 (< 19.01/> 19.01)	0.570 (0.284-1.141)	0.112
Pathological TNM stage (0-I/II-III)	0.350 (0.152-0.806)	0.014	0.342 (0.149-0.786)	0.012
NSTB score (0-1/2)			0.453 (0.234-0.877)	0.019

Model 1: Including pre-neoadjuvant chemoradiotherapy (NCRT) carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9) into multivariate analysis, not including novel serum tumor biomarker (NSTB) score; Model 2: Including NSTB score into multivariate analysis, not including pre-NCRT CEA and CA19-9. NCRT: Neoadjuvant chemoradiotherapy; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; NSTB: Novel serum tumor biomarker score; TNM: Tumor, node and metastasis.